[The correction of the imbalance in the proteinase-inhibitor system of patients with protracted pneumonia with the enterosorbent polifepan].
The evidence obtained by the authors indicates that enterosorbent polyphepan corrects unbalance in the proteinase-inhibitory system of bronchial lavage from patients with lingering pneumonia and endobronchitis. Clinical symptoms improved also. A long-term (18 days) intermittent course (0.3 g/kg 4 days with 3-day intervals) is tolerated satisfactorily, produces no side effects (no colon dysfunction), retains normal hemoglobin values, total protein, enhances antiproteinase activity. As a result of the treatment hospital stay for the above patients reduced noticeably.
Semenkova
G G
GG
Provotorov
V M
VM
Velikaia
O V
OV
D000293:Adolescent; D000328:Adult; D001991:Bronchitis / Q000378:metabolism / Q000628:therapy; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D002908:Chronic Disease; D003131:Combined Modality Therapy; D016061:Enterosorption / Q000379:methods*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008031:Lignin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000378:metabolism / Q000628:therapy*; D011480:Protease Inhibitors / Q000032:analysis*
D011480:Protease Inhibitors; C056995:polyfepan; D008031:Lignin
Korrektsiia disbalansa proteinazno-ingibitornoĭ sistemy u bol'nykh zatiazhnoĭ pnevmonieĭ énterosorbentom polifepanom.